Clinical Trial Update: Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine [Phase 1]

View source ↗

Summary

Phase 1 study evaluating (2R,6R)-Hydroxynorketamine for major depressive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• (2R,6R)-Hydroxynorketamine (Hydroxynorketamine)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED | Results posted: 2024-06-06